INTRODUCTION: In addition to radical resection, liver transplantation (LTx) is an effective treatment for hepatocellular carcinoma (HCC). However, tumor recurrence limits the efficacy of LTx in some patients. This study investigated the role of (18)F-fludeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) in predicting the prognosis of patients with HCC after LTx. METHODS: A total of 278 consecutive patients with HCC who underwent pre-LTx PET/CT were divided into derivation (n = 178) and temporal validation (n = 100) cohorts and evaluated for PET/CT values, immunohistochemical (IHC) findings, and DNA sequencing of tumor tissues. RESULTS: Patients with post-LTx recurrence exhibited significantly higher tumor maximum standardized uptake values (SUVmax) in pre-LTx PET/CT scans. Receiver operating characteristic curve analyses identified the tumor SUVmax to liver SUVmax ratio (T(SUVmax)/L(SUVmax)) as the strongest predictor of post-LTx recurrence, with an optimal cutoff value of 1.43. Kaplan-Meier analyses demonstrated that a T(SUVmax)/L(SUVmax) >1.43 was associated with a shorter time to recurrence (TTR) and overall survival (OS) in both cohorts (p < 0.001 for both). Multivariate Cox regression analyses confirmed that T(SUVmax)/L(SUVmax) >1.43 was an independent risk factor for tumor recurrence in both cohorts. IHC revealed that T(SUVmax)/L(SUVmax) >1.43 correlated with higher Ki-67 and CK19 expression. DNA sequencing indicated that tumors with T(SUVmax)/L(SUVmax) >1.43 had more mutations and a higher TMB. Furthermore, T(SUVmax)/L(SUVmax) >1.43 was significantly associated with mutations in TP53, EPPK1, MDM4, SLAMF7, SDHC, B4GALT3, RXRG, and FCGR family genes, as well as TP53 and PI3K signaling-related alterations. CONCLUSIONS: The preoperative T(SUVmax)/L(SUVmax) is a potential predictor of tumor recurrence in patients with HCC following LTx. Its use improves candidate selection and post-LTx management.
(18)F-FDG PET/CT Predicts the Prognosis of Patients with Hepatocellular Carcinoma Undergoing Liver Transplantation.
(18)F-FDG PET/CT 预测接受肝移植的肝细胞癌患者的预后
阅读:8
作者:Zheng Wen-Jing, Xu Yang, Tan Hui, Chen Shu-Guang, Wang Peng-Xiang, Sun Hai-Xiang, Li Rui-Zhe, Zeng Hai-Ying, Zhong Yu-Chen, Cheng Jian-Wen, Fan Jia, Zhou Jian, Shi Hongcheng, Yang Xin-Rong
| 期刊: | Liver Cancer | 影响因子: | 9.100 |
| 时间: | 2025 | 起止号: | 2025 Mar 5 |
| doi: | 10.1159/000544966 | 研究方向: | 细胞生物学 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
